Response.
Affiliations of authors: Department of Medical Oncology, Monash University at Cabrini Hospital, Malvern, Victoria 3144, Australia (IH); Atomic Oncology, Newport Beach, New South Wales 2106, Australia (GLGM). Ian.haines@monash.edu gmiklos@atomiconcology.com.
Ian E
IE
Haines
Affiliations of authors: Department of Medical Oncology, Monash University at Cabrini Hospital, Malvern, Victoria 3144, Australia (IH); Atomic Oncology, Newport Beach, New South Wales 2106, Australia (GLGM).
George L Gabor
GL
Miklos
D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood*; D055088:Early Detection of Cancer; D006801:Humans; D008297:Male; D008403:Mass Screening; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality*; D057832:Watchful Waiting
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen